Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS.

@article{Ibrahim2003ActivationOC,
  title={Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS.},
  author={Mohab M Ibrahim and Hongfeng Deng and Alexander Zvonok and Debra A. Cockayne and Joyce Kwan and Heriberto P Mata and Todd W. Vanderah and Josephine Lai and F rank Porreca and Alexandros Makriyannis and T. Philip Malan},
  journal={Proceedings of the National Academy of Sciences of the United States of America},
  year={2003},
  volume={100 18},
  pages={10529-33}
}
We designed AM1241, a selective CB2 cannabinoid receptor agonist, and used it to test the hypothesis that CB2 receptor activation would reverse the sensory hypersensitivity observed in neuropathic pain states. AM1241 exhibits high affinity and selectivity for CB2 receptors. It also exhibits high potency in vivo. AM1241 dose-dependently reversed tactile and… CONTINUE READING